Modulators of G3BP2-Tau interaction for treatment of Tau-related diseases

By using compounds that regulate the interaction between the NTF2-like domain and the Tau protein, the technological gap in the treatment of Tau protein diseases has been filled, achieving effective inhibition of Tau protein diseases and delaying disease progression.

CN118922719APending Publication Date: 2024-11-08F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380027305.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-14
Filing Date
2023-03-13
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Current technology provides limited understanding of the mechanisms of Tau protein diseases, resulting in a lack of effective treatments.

Method used

Compounds that promote or enhance protein-protein interactions between proteins containing NTF2-like domains or variants of a specific amino acid sequence and Tau proteins are used to treat Tau-related diseases.

Benefits of technology

By enhancing the interaction between the NTF2-like domain and Tau protein, Tau aggregation is inhibited, Tau pathological manifestations are reduced, and disease progression is delayed.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005040654000000011
    Figure HDA0005040654000000011
  • Figure HDA0005040654000000021
    Figure HDA0005040654000000021
  • Figure HDA0005040654000000031
    Figure HDA0005040654000000031
Patent Text Reader

Abstract

The present invention relates to a method for the identification of a compound that modulates the protein-protein interaction between a protein comprising the NTF2-like domain of G3BP2 having the amino acid sequence shown in Seq. Id. No.3 and a Tau protein, for use in the treatment of Tau-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to methods for treating Tau-related diseases.

[0002] Toxic accumulation of the microtubule-associated protein Tau is a hallmark of multiple neurodegenerative diseases, including Alzheimer's disease (AD), frontotemporal dementia with parkinsonism-17 (FTDP-17), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and Pick's disease (PiD); these diseases are collectively referred to as tauopathies. In the healthy brain, Tau participates in the assembly and stabilization of microtubules, whereas under disease conditions, hyperphosphorylated Tau detaches from microtubules and further aggregates to form paired helical filaments (PHFs) and neurofibrillary tangles (NFTs). The current limited understanding of the mechanisms underlying tauopathies has hampered the development of effective treatments for these diseases.

[0003] Therefore, there is a need for the identification of new target proteins and their use for the treatment of tauopathies.

[0004] In the first object, the present invention provides a method for treating a Tau-related disease, the method comprising administering to a subject an effective amount of a compound that modulates a protein-protein interaction between a protein comprising an NTF2-like domain or a variant thereof having an amino acid sequence shown in Seq.Id.No.3 and a Tau protein.

[0005] In one embodiment, the compound promotes / enhances the protein-protein interaction between a protein comprising an NTF2-like domain and a Tau protein.

[0006] In one embodiment, the compound is a mimetic of a protein-protein interaction between a protein comprising an NTF2-like domain and a Tau protein.

[0007] In one embodiment, the Tau-associated disease is selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, dementia pugilistica, Down syndrome, traumatic brain injury, Guam amyotrophic lateral sclerosis / parkinsonism-dementia complex, non-Guam motor neuron disease with neurofibrillary tangles, argyrophilic grain dementia, corticobasal degeneration, diffuse neurofibrillary tangles with calcifications, frontotemporal dementia, chromosome 17-related frontotemporal dementia with parkinsonism, Hallevorden-Spatz disease, Niemann-Pick disease type C, globus pallidus-ponto-nigral degeneration, Pick's disease, progressive subcortical gliosis, progressive supranuclear palsy, tangled dementia, postencephalitic parkinsonism, and myotonic dystrophy.

[0008] In one embodiment, the protein comprising an NTF2-like domain is a G3PB2 protein.

[0009] In one embodiment, the protein comprising an NTF2-like domain and the Tau protein are human proteins.

[0010] In a second object, the present invention provides a compound that modulates the protein-protein interaction between a protein comprising an NTF2-like domain having an amino acid sequence shown in Seq.Id.No.3 or a variant thereof and a Tau protein, wherein the compound is used for use in the treatment of a Tau-related disease.

[0011] In an embodiment of the second aspect, the Tau-associated disease is selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, dementia pugilistica, Down syndrome, traumatic brain injury, Guam amyotrophic lateral sclerosis / parkinsonism-dementia complex, non-Guam motor neuron disease with neurofibrillary tangles, argyrophilic grain dementia, corticobasal degeneration, diffuse neurofibrillary tangles with calcifications, frontotemporal dementia, chromosome 17-related frontotemporal dementia with parkinsonism, Hallevorden-Spatz disease, Niemann-Pick disease type C, globus pallidus-ponto-nigral degeneration, Pick's disease, progressive subcortical gliosis, progressive supranuclear palsy, tangled dementia, postencephalitic parkinsonism, and myotonic dystrophy.

[0012] In the third object, the present invention provides a protein comprising an NTF2-like domain or a variant thereof having an amino acid sequence shown in Seq.Id.No.3, wherein the protein is used in the identification of compounds that modulate the protein-protein interaction between the protein comprising the NTF2-like domain and the Tau protein.

[0013] In a fourth object, the present invention provides a protein comprising an NTF2-like domain or a variant thereof having an amino acid sequence as shown in Seq.Id.No.3, wherein the protein is used as a target protein for treating Tau-related diseases.

[0014] In an embodiment of the third and fourth aspects, the protein is human G3BP2 protein. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1: G3BP2 directly interacts with Tau and inhibits Tau aggregation in vitro.

[0016] 1a) SPR sensorgram and binding affinity (Kd) of full-length Tau interacting with full-length G3BP2. Tau was immobilized on a sensor chip and the corresponding concentrations of G3BP2 were injected.

[0017] 1b) Kinetics and bar graph showing the effect of G3BP2 on Tau aggregation (n=6). Error bars: mean±SD. p values ​​were obtained using one-way ANOVA followed by Dunnett's multiple comparison test (post hoc test) with controls.

[0018] FIG. 2 : Aggregated Tau species are increased upon G3BP2 knockdown as assayed by Tau seeding in hiPSC-derived neurons.

[0019] 2a) Schematic diagram of Tau seeding assay in hiPSC-derived neurons. OE: overexpression. Tau PFF: Tau pre-formed fibrils.

[0020] 2b) Quantification of aggregated Tau species in Tau seeding assay. p values ​​were obtained using a two-tailed unpaired Student's t-test.

[0021] Figure 3: Tau pathology is elevated in the absence of G3BP2.

[0022] 3a) Immunohistochemistry of phosphorylated Tau (green) and total Tau (magenta) in 4-month-old fAD (PSEN1 M139V) or fAD G3BP2 knockout human brain organoids. Nuclei were stained blue with DAPI. Scale bar: 50 μm.

[0023] 3b) Whole slide image showing IHC of Tau pS214 (green), total Tau (yellow) and MAP2 (red). Scale bar: 2 mm.

[0024] 3c) Tau pT181 and pT231 were quantified by ELISA. pTau levels were normalized to total Tau levels. Each data point represents 4 to 5 pooled hCOs. Error bars: mean ± SD. p values ​​were obtained using a two-tailed unpaired Student's t-test.

[0025] Figure 4: G3BP2-Tau interaction gradually increases in human AD brain.

[0026] 4a) Representative images showing PLA signals (green) of G3BP2 interacting with Tau in Braak I, IV, and VI AD cases. Total Tau was stained with Tau polyclonal antibody (magenta). Nuclei were stained with DAPI (blue). Scale bar: 10 μm.

[0027] 4b) Quantification of PLA spots of G3BP2-Tau per cell in patients with Braak I (n=9), II&III (n=10), IV&V (n=10), and VI (n=9) AD. For box plots, median, 25th percentile, and 75th percentile are shown. p-values ​​were obtained using a two-tailed unpaired Student's t-test. PLA: neighbor ligation assay. AD: Alzheimer's disease.

[0028] Figure 5: The NTF2-like domain of G3BP2 can inhibit Tau aggregation.

[0029] 5a) Amino acid sequence of full-length G3BP2.

[0030] 5b) Amino acid sequence of the NTF2-like domain of G3BP2 (Seq. Id. No. 3).

[0031] 5c) Kinetics and bar graph showing the effect of G3BP2 NTF2-like domain on Tau aggregation (n=5). Data are shown as mean±SD. p values ​​compared to control group were obtained using one-way ANOVA followed by Dunnett's multiple comparison test (post hoc test).

[0032] definition

[0033] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain aspects, an individual or subject is a human.

[0034] The term "pharmaceutical composition" or "pharmaceutical formulation" refers to a preparation that is in a form that permits the biological activity of the active ingredient contained therein to be effective, and that contains no additional components that are unacceptably toxic to a subject to which the pharmaceutical composition would be administered.

[0035] "Pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical composition or formulation other than the active ingredient, which is non-toxic to the subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0036] Tau proteins are often associated with microtubules and play a crucial role in the assembly of microtubules, stabilizing them against dynamic instability and promoting their association with other cytoskeletal filaments. (Mactui RB and Change V. (1995) Role of microtubule-associated proteins in the control of microtubule assembly. Physiol Rev. 75(4): 835–864; Mactui, RB, Barbeita L and JP (20001). The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch. Medical Research. 32-367-381). Tau protein belongs to the MAP (or microtubule-associated protein) family. In humans, it is almost exclusively found in neurons (Mactui RB and Arechaga J. (1987). "The Cytoskeleton in Cell Differentiation and Development". Oxford University Press, UK 367 pp; Mactui RB and Change V. (1995.) Role of microtubule-associated proteins in the control of microtubule assembly. Physiol Rev. 75 (4): 835-864) and appears in 6 subtypes, which are derived from the expression of a single gene. The gene is present at position 21 (17q21) of the long arm of chromosome 17 and contains 13 exons that generate 6 molecular isoforms with between 352 and 441 amino acids through an alternative splicing process (Goedert M. (2004). Tau protein and neurodegeneration. Seminars in Cell & Developmental Biology. 15: 45-49).

[0037] Exemplary Tau protein-associated diseases or disorders include, but are not limited to, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, dementia pugilistica, Down syndrome, traumatic brain injury, Guam amyotrophic lateral sclerosis / parkinsonism-dementia complex, non-Guam motor neuron disease with neurofibrillary tangles, argyrophilic grain dementia, corticobasal degeneration, diffuse neurofibrillary tangles with calcifications, frontotemporal dementia, chromosome 17-related frontotemporal dementia with Parkinsonism, Hallervorden-Spatz disease, Niemann-Pick disease type C, globus pallidus-ponto-nigral degeneration, Pick's disease, progressive subcortical gliosis, progressive supranuclear palsy, tangled dementia, postencephalitic parkinsonism, and myotonic dystrophy.

[0038] As used herein, "treatment" (and grammatical variants thereof, such as "treat" or "treating") refers to an attempt to alter the natural course of a disease in the individual being treated, and may be performed for prevention or clinical interventions that may be performed during clinical pathology. Desired effects of treatment include, but are not limited to, preventing the occurrence or recurrence of the disease, alleviating symptoms, attenuating any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, ameliorating or alleviating the disease state, and alleviating or improving prognosis. In some aspects, the antibodies of the invention are used to delay the development of a disease or slow the progression of a disease.

[0039] Herein, "G3BP2" is an abbreviation for Ras GTPase activating protein binding protein 2. Isoform A of human G3BP2 has Uniprot ID: Q9UN86-1 (Seq. Id. No. 1), and Isoform B of human G3BP2 has Uniprot ID: Q9UN86-2 (Seq. Id. No. 2). In addition, herein, variant G3BP2 proteins also include functional fragments or derivatives thereof.

[0040] As used herein, the term "NTF2-like domain" refers to a protein domain comprising the amino acid sequence shown in Seq.Id.No.3, and the term encompasses NTF2-like domain variants having at least 80%, 85%, 90%, 95%, and 100% amino acid sequence identity with the NTF2-like domain amino acid sequence shown in Seq.Id.No.3. NTF2-like domain variants may have a shorter amino acid sequence length, the same amino acid sequence length, or a longer amino acid sequence length than the amino acid sequence shown in Seq.Id.No.3, provided that these NTF2-like domain variants retain their ability to interact with Tau protein (functional NTF2-like domain variants). NTF2 refers to nuclear transport factor 2 protein.

[0041] As used herein, the terms “modulator” and “inhibitor” refer to compounds that reversibly or irreversibly promote / enhance and / or inhibit the protein-protein interaction between a protein containing an NTF2-like domain and a Tau protein.

[0042] As used herein, the term "mimetic" refers to a compound that structurally mimics the natural protein-protein interaction between a protein comprising an NTF2-like domain and a Tau protein.

[0043] "Amino acid sequence identity percentage (%)" relative to a reference polypeptide sequence is defined as the percentage of amino acid residues in the candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence after aligning the candidate sequence with the reference polypeptide sequence and introducing spaces (if necessary) to achieve maximum sequence identity percentage, and for the purpose of alignment without considering any conservative substitutions as components of sequence identity. Alignment for determining amino acid sequence identity percentage can be achieved in various ways within the technical scope of the art, for example, using publicly available computer software, such as BLAST, BLAST-2, Clustal W, Megalign (DNASTAR) software or FASTA program package. Those skilled in the art can determine the appropriate parameters for aligning sequences, including any algorithm required for achieving maximum alignment over the full length of the compared sequence. Alternatively, the sequence comparison computer program ALIGN-2 can be used to generate identity percentage values. The ALIGN-2 sequence comparison computer program was written by Genentech, Inc. and the source code has been filed with user documentation in the US Copyright Office, Washington DC, 20559, where it is registered under US Copyright Registration No. TXU510087 and is described in WO 2001 / 007611.

[0044] Unless otherwise indicated, for the purposes of this paper, the values ​​of amino acid sequence identity percentages are generated using the BLOSUM50 comparison matrix using the ggsearch program of the FASTA package version 36.3.8c or higher. The FASTA package is by W.R. Pearson and D.J. Lipman (1988), "Improved Tools for Biological Sequence Analysis", PNAS 85:2444-2448; W.R. Pearson (1996) "Effective protein sequence comparison" Meth. Enzymol. 266:227-258; and Pearson et al. (1997) Genomics 46:24-36 creation and available from www.fasta.bioch.virginia.edu / fasta_www2 / fasta_down.shtml or www.ebi.ac.uk / Tools / sss / fasta. Alternatively, sequences can be compared using a public server accessible at fasta.bioch.virginia.edu / fasta_www2 / index.cgi, using the ggsearch (global protein:protein) program and default options (BLOSUM50; open: -10; ext: -2; Ktup = 2) to ensure that a global rather than a local alignment is performed. The amino acid identity percentage is given in the output alignment header.

[0045] Materials and Methods

[0046] Figure 1a :

[0047] Surface plasmon resonance (SPR) experiments were performed at Agro-Bio (La Ferté-Saint-Aubin, France) in a Biacore T200 (Cytiva) equipped with BiacoreTM T200 control software (V2.0.2, Cytiva) at 25°C using HBS-EP+ as running buffer (Cytiva, Cat. BR100669). The following recombinant proteins were used in SPR. Active human recombinant Tau441 (2N4R) wild-type protein monomer (StressMarq, Cat. SPR-479), and custom His-tagged human full-length G3BP2 (1 to 449) were produced at GenScript Biotech (Piscataway, USA).

[0048] Figure 1b and Figure 5c :

[0049] To simulate Tau aggregation in vitro, recombinant Tau441 (2N4R) P301L (Analytik Jena, Cat. T-1014-1) at a final concentration of 1 μM was incubated with 30 μM sodium octadecyl sulfate (ODS) and 1 μM heparin in reagent buffer (20 μM Thioflavin T, 5 mM 1,4-dithioerythritol (DTT), 100 mM sodium chloride, 10 mM HEPES pH 7.4) in a black no-binding 96-well plate at 37° C. for 15 hours. G3BP2 at 3 concentrations (0.2, 1, and 5 μM) was incubated with Tau-heparin-ODS-buffered solution. Baseline measurements were taken immediately after preparation, and kinetics were monitored every 15 minutes for 15 hours by using 450 nm excitation and 485 nm emission fluorescence mode on a Multimode Reader Cytation5 (BioTek) while incubating at 37°C. The assay was performed at QPS Austria GmbH (Grambach, Austria). Custom His-tagged human full-length G3BP2 (1 to 449) and G3BP2 NTF2-like fragments (amino acids 1 to 139) were produced at GenScript Biotech.

[0050] Figure 2:

[0051] iCell GlutaNeurons (FUJIFILM Cellular Dynamics, Cat. R1034) were placed at 2x10 5 cells / cm 2 The density of 100 μg / ml was seeded on a 96-well plate. The cells were treated with the corresponding siRNA on the 2nd day, and then transduced with lentiviral particles (Flash Therapeutics) expressing P301S tau under the EF1a promoter at a multiplicity of infection (MOI) of 2. On the 7th day, the ultrasonic Tau pre-formed fibrils (PFF) (StressMarq, Cat. SPR-471) were added to the culture medium at a concentration of 1 μg / ml with 0.2 μl Lipofectamine 2000 (Invitrogen, Cat. 11668019) per well. On the 14th day, Tau aggregation was measured using a Tau aggregation assay kit (Cisbio, Cat. 6FTAUPEG) according to the manufacturer's instructions. The total Tau content was determined via a Tau AlphaLISA kit (Perkin Elmer, Cat. AL271).

[0052] Figure 3:

[0053] The fAD iPSC (SFC805-03-01) line was obtained from the StemBANCC Consortium. To generate G3BP2KO fAD iPSCs, two sgRNAs, G3BP2_1 5'-UUGUAGGGCGGGAGUUUGUG-3' (Seq. Id. No. 4) and G3BP2_2 5'-GUCGUUGUUCACGCACACG-3' (Seq. Id. No. 5) (150 pmol / reaction) (Synthego, USA), and TrueCutCas9 protein v2 (50 pmol / reaction) were used. hiPSC-derived hCOs were generated using the STEMdiff Brain Organoid Kit (STEMCELL Technologies, Cat. 08570) according to the manufacturer's instructions.

[0054] For immunohistochemistry, hCO were fixed with 4% paraformaldehyde (PFA) at room temperature for 3 hours, washed with PBS and immersed in 30% sucrose solution at 4°C overnight. PFA-fixed organoids were embedded in OCT compound (Sakura Finetek, Cat. 4583) and stored at -80°C. Organoid blocks were cut at 10 μm on a cryostat. For IHC, sections were permeabilized in 0.1% Triton X-100 and blocked with animal-free blocking agent (Vector Laboratories, Cat. SP-5030) for 30 minutes. Tissue sections were incubated with primary antibodies diluted in blocking solution at room temperature for 1 hour, washed three times with PBS-T, and further incubated with secondary antibodies at room temperature for 1 hour. After washing with PBS-T, the sections were incubated with PureBlu DAPI (Bio-Rad, Cat. 1351303) for 3 minutes and sealed with ProLong Gold anti-fluorescence quenching sealing solution (Invitrogen, Cat. P36934). In IHC, the following primary antibodies were used: G3BP2 (Novus, Cat. NBP1-82976), NeuN (Boster Bio, Cat. M11954-3), Tau pT231 (abcam, Cat. ab151559), Tau pT181 (abcam, Cat. ab254409) and Tau pS214 (abcam, Cat. ab170892). Species-specific AlexaFlour-conjugated secondary antibodies (Invitrogen) were used in this study. Fluorescence images were acquired using an SP8 confocal microscope (Leica, Germany) and an Olympus SLIDEVIEW VS200 (Olympus, Japan) slide scanner.

[0055] hCO lysate was prepared using CytoBuster protein extraction reagent (Millipore, Cat. 71009) supplemented with EDTA-free cOmplete protease inhibitor tablets (Roche, Cat. 11836170001) and PhosSTOP tablets (Roche, Cat. 4906845001). Total tau levels were measured by human Tau AlphaLISA detection kit, and the levels of Tau pT231 and Tau pT181 were quantified using the corresponding enzyme-linked immunosorbent assay (ELISA) kits (Thermo Fisher Scientific, Cat. KHB8051 and KHO0631) according to the manufacturer's instructions.

[0056] Figure 4:

[0057] Duolink proximity ligation assay (PLA) assays were performed according to the manufacturer's instructions. Briefly, tissue sections were treated and incubated with antibodies as described for immunohistochemistry. PLA was performed using anti-rabbit PLUS (Sigma, Cat. DUO92002), anti-mouse MINUS (Sigma, Cat. DUO92004) probes, and in situ detection reagent-green (Sigma, Cat. DUO92014). After PLA, slides were incubated with PureBlu DAPI for 3 minutes and sealed with ProLong Gold anti-fluorescence quenching mounting fluid. Fluorescence images were acquired using an SP8 confocal microscope. Images were scanned using an Olympus SLIDEVIEW VS200 slide scanner for quantification. In PLA, the following primary antibodies were used: Tau HT7 (Thermo Fisher Scientific, Cat. MN1000), G3BP2 (Novus, Cat. NBP1-82976), and Tau polyclonal antibody (Novus, Cat. NBP2-25163).

[0058] For PLA quantification of brain sections, sections were scanned using an Olympus Slideview VS200 slide scanner, and more than 9000 cells were counted per patient on average. Nuclei and PLA spots were quantified using the Track Mate LoG detector (ImageJ), with the same estimated spot diameter and threshold in each experiment. Then, for each patient, the number of PLA spots was normalized to the total number of cells.

Claims

1. A method for treating a Tau-related disease, the method comprising administering to a subject an effective amount of a compound that modulates a protein-protein interaction between a protein comprising an NTF2-like domain or a variant thereof having an amino acid sequence as shown in Seq.Id.No.3 and a Tau protein. 2 . The method according to claim 1 , wherein the compound promotes / enhances the protein-protein interaction between the protein comprising the NTF2-like domain and Tau protein.

3. The method of claim 1, wherein the compound is a mimetic of the protein-protein interaction between the protein comprising an NTF2-like domain and Tau protein.

4. The method of claims 1 to 3, wherein the Tau-associated disease is selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, dementia pugilistica, Down syndrome, traumatic brain injury, Guam amyotrophic lateral sclerosis / parkinsonism-dementia complex, non-Guam motor neuron disease with neurofibrillary tangles, argyrophilic grain dementia, corticobasal degeneration, diffuse neurofibrillary tangles with calcifications, frontotemporal dementia, chromosome 17-associated frontotemporal dementia with parkinsonism, Hallervorden-Spatz disease, Niemann-Pick disease type C, globus pallidus-ponto-nigral degeneration, Pick's disease, progressive subcortical gliosis, progressive supranuclear palsy, tangled dementia, postencephalitic parkinsonism, and myotonic dystrophy. 5 . The method according to claim 1 , wherein the protein comprising the NTF2-like domain is G3PB2 protein. The method according to claims 1 to 5, wherein the protein comprising the NTF2-like domain and the Tau protein are human proteins.

7. A compound that modulates the protein-protein interaction between a protein comprising an NTF2-like domain having an amino acid sequence as shown in Seq.Id.No.3 or a variant thereof and a Tau protein, wherein the compound is used for the treatment of a Tau-related disease.

8. The compound for use according to claim 7, wherein the Tau-related disease is selected from the group consisting of: Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, dementia pugilistica, Down syndrome, traumatic brain injury, Guam amyotrophic lateral sclerosis / parkinsonism-dementia complex, non-Guam motor neuron disease with neurofibrillary tangles, argyrophilic grain dementia, corticobasal degeneration, diffuse neurofibrillary tangles with calcifications, frontotemporal dementia, chromosome 17-related frontotemporal dementia with parkinsonism, Hallervorden-Spatz disease, Niemann-Pick disease type C, globus pallidus-ponto-nigral degeneration, Pick's disease, progressive subcortical gliosis, progressive supranuclear palsy, tangled dementia, postencephalitic parkinsonism and myotonic dystrophy.

9. A protein comprising an NTF2-like domain or a variant thereof having an amino acid sequence as shown in Seq.Id.No.3, for use in identifying a compound that modulates the protein-protein interaction between the protein comprising the NTF2-like domain and Tau protein.

10. A protein comprising an NTF2-like domain or a variant thereof having an amino acid sequence as shown in Seq.Id.No.3, wherein the protein is used as a target protein for treating Tau-related diseases.

11. The protein for use according to claim 9 or 10, wherein the protein is human G3BP2 protein.